Signant Health has expanded its mobile patient engagement app, TrialGuide, with integrated virtual visit capabilities.
Initially launched to aid existing customers dealing with the patient-site communication challenges presented by Covid-19, virtual visits have been extended for all sponsors and CROs as the firm continues to speed up its product development roadmap to meet the evolving requirements of clinical research across the world.
Virtual visits offer more choice for patients and clinicians in enhancing the patient experience and supporting trial continuity, now and in the future.
By bringing together virtual face-to-face communication with right remote evaluations, and a direct to patient clinical supply chain, Signant Health claims to offer flexibility for patients, sites, and study teams on how, and where, clinical research is carried out.
A patient engagement solution, TrialGuide comes with features that complement virtual visits, including SMS messaging, compliance reminders, visit schedule management, caregiver support, multimedia and animated content, gamification, third-party integration with patient stipend balances, and rapid deployment capabilities.
In addition to patient engagement, Signant Health’s combined suite of patient solutions, including clinical supply chain management and endpoint quality services, are claimed to have aided customers overcome the unforeseen challenges presented by Covid-19 and prepare for new realities in clinical research by aiding trial continuity and launching clinical trials faster than before.
Signant Health chief commercial officer Ian Jennings said: “The Covid-19 pandemic illustrated how important patient-site connectivity is to the success of clinical research and our goal is to make it easier for patients to participate and communicate in trials without the technology getting in their way.
“Whether that means enabling eCOA data capture, remote consent, and video visits on a single device, deploying IRT in record time to randomise and supply patients as quickly as possible, or equipping raters with the training and tools they need to make consistent assessments remotely, we are here to support our customers who are working hard to keep their trials running and bring new treatments to people who need them worldwide.”